EB-PSMA-617
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 125682

CAS#: N/A

Description: EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.


Chemical Structure

img
EB-PSMA-617
CAS# N/A

Theoretical Analysis

MedKoo Cat#: 125682
Name: EB-PSMA-617
CAS#: N/A
Chemical Formula: C87H110N16O28S3
Exact Mass: 1,922.68
Molecular Weight: 1,924.100
Elemental Analysis: C, 54.31; H, 5.76; N, 11.65; O, 23.28; S, 5.00

Price and Availability

Size Price Availability Quantity
5mg USD 1650 2 Weeks
10mg USD 2950 2 Weeks
100mg USD 6950 2 Weeks
Bulk inquiry

Synonym: EB-PSMA-617; EB-PSMA 617; EB PSMA-617; EB PSMA 617; EB-PSMA617;

IUPAC/Chemical Name: (((1S)-5-((2S)-2-(4-((2-((1-(2-(((S)-6-((4'-((8-amino-1-hydroxy-5,7-disulfonaphthalen-2-yl)diazenyl)-3,3'-dimethyl-[1,1'-biphenyl]-4-yl)amino)-6-oxo-5-(2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetamido)hexyl)amino)-2-oxoethyl)-2,5-dioxopyrrolidin-3-yl)thio)acetamido)methyl)cyclohexane-1-carboxamido)-3-(naphthalen-2-yl)propanamido)-1-carboxypentyl)carbamoyl)-L-glutamic acid

InChi Key: ZZOPIXCOCDFJQS-QWPCFAHTSA-N

InChi Code: InChI=1S/C87H110N16O28S3/c1-50-37-57(58-20-23-61(51(2)38-58)97-98-62-24-21-59-68(133(126,127)128)42-69(134(129,130)131)79(88)78(59)80(62)116)19-22-60(50)93-83(119)63(92-71(105)44-99-29-31-100(46-75(110)111)33-35-102(48-77(114)115)36-34-101(32-30-99)47-76(112)113)11-5-7-27-89-70(104)45-103-73(107)41-67(84(103)120)132-49-72(106)91-43-52-13-17-55(18-14-52)81(117)94-66(40-53-15-16-54-9-3-4-10-56(54)39-53)82(118)90-28-8-6-12-64(85(121)122)95-87(125)96-65(86(123)124)25-26-74(108)109/h3-4,9-10,15-16,19-24,37-39,42,52,55,63-67,116H,5-8,11-14,17-18,25-36,40-41,43-49,88H2,1-2H3,(H,89,104)(H,90,118)(H,91,106)(H,92,105)(H,93,119)(H,94,117)(H,108,109)(H,110,111)(H,112,113)(H,114,115)(H,121,122)(H,123,124)(H2,95,96,125)(H,126,127,128)(H,129,130,131)/t52-,55-,63-,64?,65?,66-,67?/m0/s1

SMILES Code: O=C(CN1CCN(CCN(CCN(CC1)CC(O)=O)CC(O)=O)CC(O)=O)N[C@H](C(NC2=CC=C(C3=CC=C(N=NC4=C(O)C(C(N)=C(S(=O)(O)=O)C=C5S(=O)(O)=O)=C5C=C4)C(C)=C3)C=C2C)=O)CCCCNC(CN6C(CC(SCC(NC[C@@H]7CCC(C(N[C@H](C(NCCCC[C@H](NC(N[C@@H](CCC(O)=O)C(O)=O)=O)C(O)=O)=O)CC8=CC9=C(C=CC=C9)C=C8)=O)CC7)=O)C6=O)=O)=O

Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 1,924.10 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Zang J, Fan X, Wang H, Liu Q, Wang J, Li H, Li F, Jacobson O, Niu G, Zhu Z,
Chen X. First-in-human study of 177Lu-EB-PSMA-617 in patients with
metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging.
2019 Jan;46(1):148-158. doi: 10.1007/s00259-018-4096-y. Epub 2018 Aug 8. PMID:
30090965; PMCID: PMC6250576.

2: Lu Q, Long Y, Gai Y, Liu Q, Jiang D, Lan X. [177Lu]Lu-PSMA-617
theranostic probe for hepatocellular carcinoma imaging and therapy. Eur J Nucl
Med Mol Imaging. 2023 Jul;50(8):2342-2352. doi: 10.1007/s00259-023-06155-x. Epub
2023 Mar 6. PMID: 36877233.

3: Zang J, Liu Q, Sui H, Wang R, Jacobson O, Fan X, Zhu Z, Chen X.
177Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients
with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2020
Dec;61(12):1772-1778. doi: 10.2967/jnumed.120.242263. Epub 2020 May 1. PMID:
32358086; PMCID: PMC9364902.

4: Wang Z, Tian R, Niu G, Ma Y, Lang L, Szajek LP, Kiesewetter DO, Jacobson O,
Chen X. Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand
Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors. Bioconjug
Chem. 2018 Sep 19;29(9):3213-3221. doi: 10.1021/acs.bioconjchem.8b00556. Epub
2018 Aug 22. PMID: 30105912.

5: Wen X, Xu P, Zeng X, Liu J, Du C, Zeng X, Cheng X, Wang X, Liang Y, Zhao T,
Yang H, Li H, Meng L, Fang J, Liu H, Zhou Z, Zhang J, Zhang X, Guo Z, Chen X.
Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate
cancer with a moderate level of PSMA expression. Eur J Nucl Med Mol Imaging.
2023 Jul;50(9):2846-2860. doi: 10.1007/s00259-023-06229-w. Epub 2023 Apr 25.
PMID: 37097443.

6: Ghodsirad MA, Pirayesh E, Akbarian R, Javanmard B, Kaghazchi F, Tavakoli M,
Fattahi K. Diagnostic Utility of Lutetium-177 (Lu 177) Prostate-Specific
Membrane Antigen (PSMA) Scintigraphy In Prostate Cancer Patients With PSA Rise
And Negative Conventional Imaging. Urol J. 2020 Jun 23;17(4):374-378. doi:
10.22037/uj.v0i0.5451. PMID: 32281092.